The BCl-2 family has long been identified for its role in apoptosis. Following the initial discovery of BCL-2 in the context of B-cell lymphoma in the 1980s, a number of homologous proteins have since been identified. The members of the Bcl-2 family are designated as such due to their BCL-2 homology (BH) domains and involvement in apoptosis regulation. The BH domains facilitate the family members' interactions with each other and can indicate pro-or antiapoptotic function. Traditionally, these proteins are categorised into one of the three subfamilies; anti-apoptotic, BH3-only (pro-apoptotic), and pore-forming or 'executioner' (pro-apoptotic) proteins. Each of the BH3-only or antiapoptotic proteins has a distinct pattern of activation, localisation and response to cell death or survival stimuli. All of these can vary across cell or stress types, or developmental stage, and this can cause the delineation of the roles of BCL-2 family members. Added to this complexity is the presence of relatively uncharacterised isoforms of many of the BCL-2 family members. There is a gap in our knowledge regarding the function of BCL-2 family isoforms. BH domain status is not always predictive or indicative of protein function, and several other important sequences, which can contribute to apoptotic activity have been identified. While therapeutic strategies targeting the BCL-2 family are constantly under development, it is imperative that we understand the molecules, which we are attempting to target. This review, discusses our current knowledge of anti-apoptotic BCL-2 family isoforms. With significant improvements in the potential for splicing therapies, it is important that we begin to understand the distinctions of the BCL-2 family, not limited to just the mechanisms of apoptosis control, but in their roles outside of apoptosis.
BCL-2 family members play an integral role in apoptosis, but also contribute to many other cellular functions.
• Isoforms of almost all of the BCL-2 family members have been identified and some are well characterised.
• Therapeutics targeting BCL-2 show great promise for the treatment of cancer.
Open questions
• What is the functional role of uncharacterised BCL-2 family member isoforms in apoptosis and normal cellular functions, in particular the BCL-2 isoform BCL-2β?
Introduction
The BCl-2 family has long been identified for its role in apoptosis. Following the initial discovery of BCL-2 in the context of B-cell lymphoma in the 1980s, a number of homologous proteins have since been identified [1] [2] [3] . The members of the Bcl-2 family are designated as such due to their BCL-2 homology (BH) domains and involvement in apoptosis regulation. The BH domains facilitate the family members' interactions with each other, and can indicate pro-or anti-apoptotic function 4, 5 . Traditionally, these proteins are categorised into one of three subfamilies; anti-apoptotic, BH3-only (pro-apoptotic), and poreforming or 'executioner' (pro-apoptotic) proteins. Subfamily categorization has been traditionally based on BH and transmembrane domain and anti-or pro-apoptotic function status, as well as pore-forming ability (as shown in Table 1 ).
The role of the BCL-2 family in apoptotic regulation is typically described as the anti-apoptotic and proapoptotic BH3-only members existing in a state of competitive flux to influence the activation of the poreforming executioners 6, 7 . The ratio of pro-to antiapoptotic subfamily members present in a cell can be altered by a number of signalling pathways, effectively relaying information on cellular stress, such as available nutrients, DNA damage, and protein processing 8 . Once the executioners are activated, the molecules come together to form pores in the outer mitochondrial membrane (MOM) and thus trigger mitochondrial outer membrane permeability (MOMP), and therefore apoptosis [9] [10] [11] . The BH domains are considered central to subfamily categorization as they facilitate the interaction of family members. BH3 was initially highlighted as an important domain as it was demonstrated to be vital for the interaction of the anti-apoptotic BCL-X L and the executioner BAK, as well as for its apoptotic activity. The BH3 domain is vital for the correct folding of a hydrophobic pocket, within which BCL-2 members can interact 12, 13 . Consequently, point mutations or deletions of the BH3 domain have been shown to significantly reduce the pro-apoptotic activity of a number of BH3-only proteins 14 . The BH4 domain is thought to be similarly significant for the antiapoptotic subfamily; deletion of the BH4 domain can switch function to pro-apoptotic, while retention of the BH4 domain alone is sufficient to block changes in mitochondrial potential 14 . Beyond this understanding of a competitive flux, there are several hypotheses regarding how the BCL-2 family members interact, including direct and indirect interactions amongst family members (summarised in Supplementary Table 1 ). Each of the BH3-only or anti-apoptotic proteins have patterns of activation, localisation and response to specific death or survival stimuli. Binding selectivity between members of the different classes of BCL2 proteins also varies, for example, some BH3-only proteins bind non-specifically to several BCL2 prosurvival proteins while others tend to bind in a more specific manner. Similarly, BCL2 prosurvival family members can selectively bind to and limit activity of BAX or BAK. All of these interactions can vary across cell or stress types, or developmental stage, and this can cause the delineation of the roles of BCL-2 family members. Added to this complexity is the presence of relatively uncharacterised isoforms of many of the BCL-2 family members.
BCL-2 anti-apoptotic subfamily
This review focuses on the BCL-2 anti-apoptotic subfamily and known isoforms. Traditionally, members of this family are identified by their anti-apoptotic activity as well as the presence of BH4 and transmembrane domains for anchoring to cellular membranes 15 . Some members of this anti-apoptotic subfamily lack some of these physical features, have isoforms translated from the same gene which actually have pro-apoptotic activity, or can have their activity modulated by posttranslational modification, as reviewed below and summarised in Table 2 . [3] Role unknown: Low expression in healthy cells compared to BCL2α; increased ratio of expression in blood and bone marrow of CML patients [109] BCL-2α
BCL-2β
BCL-X/BCL2L1
Anti-apoptotic: confers survival when overexpressed in cell lines deprived of growth factor [19] . Overexpression in tumours can increase risk of metastasis [110] .
Pro-apoptotic: inhibits BCL-2 from enhancing survival, generally expressed in cells with high turnover rate [19] , can sensitise cells to chemotherapy agents [54] .
BCL-X L BCL-X S

MCL-1
Anti-apoptotic: increases when cells are exposed to cell-survival inducing tumorigenic compounds, expressed in viable cells [108] .
Pro-apoptotic [108] : Very low expression in oral cancer tissue compared to MCL-1 Pro-apoptotic [59] : Very low expression in oral cancer tissue compared to MCL-1 [111] MCL-1L
MCL-1S
MCL-1ES
BCL-X
The BCL-X or BCL2L1 (BCL2-like 1) gene has 44% homology to BCL-2. It has two well-known isoforms, BCL-X L and BCL-X S (Table 2) , as well as a number of other characterised isoforms 16, 17 . The two major isoforms arise from alternative splicing of BCL-X; splicing at the distal end of the 5′ splice site within the first coding exon for production of BCL-X L and at the proximal end for BCL-X S . Interestingly, the two isoforms have a different role in apoptosis. While BCL-X L is anti-apoptotic, BCL-X S is pro-apoptotic. Overexpression of BCL-X L , but not BCL-X S , confers survival in IL-3-dependent cells following IL-3 deprivation 18 . Transfection of these IL-3-dependent cells with BCL-X S reinstates their sensitivity to IL-3 removal, regardless of levels of anti-apoptotic BCL-2 19 . This protective effect has been seen in several cell types, in response to chemotherapeutic drug treatment and growth factor removal 20 . The BCL-X L protein is comprised of seven alpha-helices, where the two central hydrophobic helices (α5 and α6) are surrounded by five amphipathic helices (α3, α6, α1, α2, and α7). The BH1, BH2, and BH3 domains sit in close proximity, and form a hydrophobic cleft for binding other family members. The C-terminal transmembrane domain extends from the α7 helix. The N-terminal helix (α1) is essential for maintenance of structure stabilisation as it forms extensive interactions with the other helices. The BH3 domain is contained within the α2 helix, the BH1 domain across the α4 and α5, and BH2 across α6 and α7 21 .
The protein structure of BCL-X S has not been comprehensively described, but the loss of both BH1 and BH2 domains would significantly alter the hydrophobic binding cleft 22 . While BCL-X L exerts its anti-apoptotic regulation by formation of heterodimers with both BAX and BAK, the pro-apoptotic function of BCL-X S is derived from its capacity to disrupt the BAK/VDAC complex through its interaction with voltage-dependent anion channel (VDAC), thus freeing BAK for activation 23 . This highlights the difference in binding capacity between the two isoforms.
Since this discovery of the alternate functions of the two variants, the mechanisms of splicing control of the BCL-X gene have been a matter of some interest. It has been demonstrated that switching of splicing favour is induced by cellular stress, specifically DNA damage 24, 25 , protein synthesis stalling 26 , and protein kinase C inhibition 27, 28 . The induction of generic cellular stress via treatment with the drug ceramide as well as the combination of epigallocatechin-3-gallate (EGCG) and non-steroidal anti-
BCL-W/BCL2L2 (BCL2-like 2)
Anti-apoptotic: increased expression confers resistance to multiple cytotoxic insults [112] Unknown.
BCL-W (Isoform 1) BCL-W (Isoform 2)
BFL-1/A1
Anti-apoptotic: Confers survival advantage in monocytes [113] , correlation between expression and stomach cancer development [114] .
Anti-apoptotic: The protein is localised to the nucleus and has antiapoptotic activity [115] .
inflammatory (ibuprofen) have also been shown to shift splice favour 29, 30 . Immunoprecipitation assays on known regulatory regions have identified proteins essential to BCL-X splice control, such as HNRNPK and PTBP1 31, 32 . In addition, investigation of known pro-apoptotic transcription factor targets (SC35 via E2F1) 25 , RNA binding proteins (SAM68, SAP155) 33, 34 , splice modulators (hnRNP F/H, SRp30c, RBm25, Akt SUMO, TCERG1) [35] [36] [37] [38] [39] , and pathways demonstrated to shift Bcl-Xs splicing favour (SB1 and RBM25) 24, 37 , have identified a number of other spliceosomal and RNA binding proteins which are involved in BCL-X splicing regulation. As well as these proteins, a lncRNA, RNA INXS, transcribed from the opposite strand of BCL-X, and proto-oncogenes FBI-1 and FYN, are capable of modulating SAM68 activity in favour of BCL-X S splicing 40, 41 . BCL-X L is also known to be involved in calcium signalling regulation via IP3R and VDAC1 42, 43 , can regulate Ca 2+ homeostasis when localised at the endoplasmic reticulum 44 and reduce mitochondrial Ca 2+ uptake 45 . The RNA-binding protein HuR, a translational repressor of BCL-X L , can also affect maintenance of mitochondrial morphology, which regulates cellular apoptosis, through translational control of BCL-X L expression 46 . BCL-X L has been linked to non-apoptotic cell death by binding the tumour suppressor Beclin 1, subsequently inhibiting autophagy 47 . The overexpression of BCL-X L has been shown to protect endothelial cells from TNF-mediated apoptosis and is involved in inflammatory response by inhibiting the activation of NF-κB and thus the upregulation of proinflammatory genes 48 . Interestingly, BCL-X L has also been shown to have apoptosis-independent function in metastasis in pancreatic neuroendocrine tumour and breast cancer cell lines via nuclear promotion of epithelial-mesenchymal transition, migration, invasion and stemness 49 and in chemoresistance via RAS interaction and influence on EMT and regulation of cancerinitiating cell (CICs) 50 . Interestingly, despite the mass of research conducted on BCL-X L and BCL-X splicing control, there is relatively little known about BCL-X S . It is a BAK-dependent proapoptotic protein 23, 51, 52 , but any roles outside of apoptosis regulation have not yet been identified. Induction of an increased ratio of BCL-X S to BCL-X L or overexpression of BCL-X S in cancer cell lines have been shown to have a pro-apoptotic effect 20, [53] [54] [55] .
MCL-1
MCL-1 (myeloid leukemia sequence 1) was initially discovered due to its upregulation in the MC-1 hematopoietic cell line during the differentiation from monocyte to macrophage 56 . At the time of discovery, the MCL-1L transcript was the only known transcript, and it was rapidly designated as anti-apoptotic after overexpression was observed to protect cells from heat shock 57 . However, there are now three known isoforms of the gene; MCL-1L, MCl-1S and MCL-1ES (Table 2 ). Similar to the BCL-X isoforms, the three proteins have different roles in the regulation of apoptosis; MCL-1L is anti-apoptotic, while MCL-1S and MCL-1ES are both pro-apoptotic 58, 59 . The C-terminal domain of MCL-1L is 350 amino acids long and has sequence homology with BCL-2. A central hydrophobic helix (α5) is surrounded by a set of amphipathic helices, which pack tightly against it (α1,
60
. MCL-1L also harbours a C-terminal transmembrane domain 58, 60 . Unlike other members of the BCL-2 family, the MCL-1L N-terminus contains a PEST sequence that is associated with rapidly degrading proteins, as well as multiple sites for phosphorylation and caspase cleavage sequences 61 . These post-translational modifications can change protein stability and function, and consequently, MCL-1L has a high rate of turnover within the cell and its degradation can be modulated at several points along the N-terminus 58, 62 . Alternatively, skipping of the second exon of the MCL-1 gene gives rise to the 271 amino acid MCL-1S (Table 2) . This variant retains the BH3, BH4 and PEST domains, but not the BH1, BH2 and transmembrane domains. This gives rise to an isoform with features characteristic of a BH3-only protein, in which heterodimerization with antiapoptotic MCL-1L can block its pro-apoptotic activity. In addition, MCL-1S is incapable of binding with BAX, BAK and BIM, whereas BCL-X L interacts strongly with these family members 58 . Besides this initial study that described the key features of MCL-1S, there is relatively little known about the protein.
A third isoform, MCL-1ES, has also been identified. MCL-1ES occurs as a result of alternative splicing within the first exon at a non-canonical donor-acceptor site. The resultant protein is 197 amino acids long and lacks the PEST sequence and BH4 domain present in the other MCL-1 isoforms (Table 2 ). This isoform displays a proapoptotic function, with overexpression of this isoform resulting in decreased resting cell viability and mitochondrial integrity, all leading to cell death 59 . Interestingly, the effects are amplified when MCL-1ES is cotransfected with MCL-1L, an anti-apoptotic family member 59 . Further work has demonstrated that MCL-1ES localisation to the mitochondria and consequent proapoptotic activity is dependent on its heterodimerization with MCL-1L 59, 63 . Interestingly, the effect of overexpression on apoptosis is BAX/BAK-dependent, and preliminary studies indicate that MCL-1ES can form the mitochondrial pores for the initiation of apoptosis by the release of cytochrome c and activation of MOMP. This activity is dependent on the BH3 domain of MCL-1ES 63 . Although studies have been performed on splicing control between MCL-1L and MCL-1S, the mechanisms of MCL-1ES splicing control are still unknown. Much of the work in delineating MCL-1 splicing regulators was performed in parallel with BCL-X investigations. For example, treatment of prostate cancer cell lines with EGCG/ibuprofen switched splicing favour to the proapoptotic variant for both MCL-1 and BCL-X in a protein phosphatase 1 (PP1)-dependent manner 30 . In addition, a study by Moore et al. (2010) identified that the splicing regulator ASF/SF2, and protein kinases PLK1 and WEE1, can shift splicing in favour of MCL-1S 64 . The same study identified SAP155 as a driver for transcription of proapoptotic splice variants for both MCL-1 and BCL-X, and this result has since been validated by other studies 64, 65 . These data indicate that MCL-1 splicing regulation is associated with cell cycle control.
Of the three isoforms, only MCL-1L has been found to have roles outside of apoptosis. Like BCL-2 and BCL-X L , MCL-1L can regulate autophagy, mitochondrial morphology, and calcium signalling via its interaction with IP3R 66 , and is involved in cell cycle control 61 and lipid metabolism 67 .
BCL-2
BCL-2 was the first member of the family to be identified, due to its role in B-cell lymphoma. A chromosomal translocation between chromosomes 14 and 18 in this disease, t(14:18), causes enhancement of BCL-2 transcription, which confers a survival advantage to the cancerous cells [1] [2] [3] . The BCL-2 gene is comprised of three exons; the first two exons encode the four BH domains, whereas the exon 3 encodes the transmembrane domain that anchors the protein to intracellular membranes 68, 69 ( Fig. 1) . There are two isoforms of BCL-2; BCL-2α and BCL-2β. While BCL-2α is anti-apoptotic 3, [70] [71] [72] , BCL-2β is yet to be fully characterised. It lacks exon 3 and thus the transmembrane-anchoring domain, but otherwise shares the same BH domains and general structure of BCL-2α (Fig. 1) . BCL-2β also has an isoform-specific 9-amino acid stretch at its C-terminal domain 73 ( Table 2) .
Roles of BCL-2α
The structure of the BCL-2α protein is similar to BCL-X L , with two central hydrophobic helices (α1 and α2) surrounded by five α-helices, and a C-terminal transmembrane domain. Like BCL-X L , this characteristic hydrophobic groove is comprised of helices 3, 4, 5 and 6. The structure of the BCL-2β protein is yet to be ascertained, but is known to lack the transmembrane domain, although the significance of this is unclear. While several studies have concluded that a C-truncated BCL-2α is incapable of localising to appropriate organelles, bind target proteins or regulate apoptosis [74] [75] [76] [77] [78] , others have disputed the significance of a transmembrane domain [79] [80] [81] . However, it is important to note that all these studies have been performed on truncated BCL-2α but not on wildtype BCL-2β.
BCL-2α binds to BAX via its BH1 and BH2 domains, and this interaction is central to its role in apoptosis regulation, as demonstrated in cell lines in response to 5 . However, in several models of stress, such as gamma irradiation, IL-3 deprivation of dependent cells, glucocorticoid and cytotoxic drug treatment, and heat shock, it has been shown that, where BCL-2 is upregulated and capable of binding BAX, the capacity of cells to undergo apoptosis is reduced 3, [70] [71] [72] . These investigations have emphasised the significance of the BH domains.
Like MCL-1L and BCL-X L , BCL-2α is the most extensively studied isoform and is involved in autophagy via interaction with Beclin 1, as well as calcium signalling, and has roles outside of apoptosis regulation 82, 83 . Interestingly, the interaction between BCL-2 and Beclin 1 occurs at the same site as BH3-only proteins and so competition for the site exists between these proteins 84 . It has also been implicated in DNA repair, including nucleotide excision repair, base excision repair, mismatch repair and double-strand break repair 82, [85] [86] [87] . In addition, BCL-2α can regulate a number of major transcription factors, including p53 88 , NF-κB, AP1, CRE and NFAT 77 . The different roles of BCL-2α are summarised in Table 3 .
Current evidence for a role of BCL2β
Despite the accumulation of evidence for the many roles of BCL-2α, there has been very little investigation into the role of BCL-2β. Functional protein studies on BCL-2 primarily focuses on the wildtype BCL-2α. Where the BCL-2β isoform is addressed, a recombinant version of a C-terminal-truncated BCL-2α is used for characterisation studies and it has been assumed this structure shares the same function as BCL-2β, as both lack the transmembrane domain 73 . Characterisation studies on the BCL-2β isoform have so far been limited to cloned versions of the genes, which do not accurately reflect the naturallyoccurring sequence 74, 76, 78, 89 . Cells with higher expression of BCL-2 had lower levels of end joining and vice versa. This was thought to be due to the ability of BCL-2 to interact with KU proteins, which form a molecular scaffold for the DSBR machinery 87, 121 .
BCL-2 can also regulate DSBR via its interaction with Studies that have assessed the significance of the transmembrane domain on the capacity for BCL-2 to regulate apoptosis and p53 and to interact with BAX and BRCA1 concluded that the domain was vital for the efficiency of BCL-2 in these roles 74, 76, 78, 90 . In contrast, studies that have concluded that the transmembrane domain is not essential for function were focused on the separate steps of apoptosis activation and/or apoptosis across different cell types 79, 80 . Despite these inconsistencies in the literature, it is important to note that C-terminaltruncated BCL-2α does not accurately represent BCL-2β, due to the isoform's specific 9-amino acid C-terminal sequence (see Fig. 2 ).
Targeting the BCL2 family for therapeutic purposes
As the BCL-X and BCL-2 families have essential roles in apoptotic regulation and were initially discovered in the cancer setting, they have garnered interest as therapeutic targets. Several studies have tried to regulate apoptosis using retroviral systems 91 , alteration of localisation apparatus 92 , activity-blocking antibodies 93 , RNAi 94 and miRNAs 95 . However, the most successful method so far for targeting the BCL-2 family has been through BH3-mimetic molecules.
BH3-mimetics
Initial proof-of-concept studies that highlighted the potential of BH3-mimetics showed that small molecules which bound to the hydrophobic groove of BCL-X L could block anti-apoptotic function 96 . Since then, many different BH3-mimetics have been developed, and these are summarized in Table 4 .
Several studies have highlighted the significance of low MCL1 expression conferring sensitivity to BH3-mimetics in cell lines 97, 98 . MCL-1L is one of the most potent of the BCL-2 family as it has a significantly high affinity with pro-apoptotic members. Several molecules with the potential for binding MCL-1L have been developed, A-1210477 was an early molecule proposed to act directly on MCL-1L to promote apoptosis in cell lines 99, 100 . More recently, S63845 a small molecule that binds with high affinity to the BH3-binding groove of MCL1 has been shown to kill MCL1-dependent cancer cells, including multiple myeloma, leukaemia and lymphoma cells 101 .
Manipulation of splicing
Splicing alters the function of BCL-2 members, therefore there is potential to target this therapeutically by manipulation of gene splicing to favour pro-apoptotic . Channels are formed by α-helices 5 and 6 124 . Phosphorylation by MAPK8 (mitogen-activated kinase 8) at specific residues between BH4 and BH3 can modify binding to Beclin-1 125 . Caspase-3 cleavage at amino acids 34-35 can abrogate protein function 126 . The two proteins are identical up to amino acid 196, where they start to differ, with BCL-2β lacking a transmembrane domain and having a specific C-terminal 9-amino acid sequence 73 . This figure was adapted from Belka and Budach (2002) transcripts. Introduction of splicing-switching oligonucleotides that alter BCL-X splicing from BCL-X L to the pro-apoptotic BCL-X S in melanoma cell culture and tumour xenografts was shown to reduce tumour load 102 . Additionally, the transcription factor FBI-1 has been shown to have a role in alternative splicing by interacting with splicing factor SAM68, thus reducing binding of SAM68 to BCL-X and resulting in the preferential splicing of anti-apoptotic BCL-X L 41 . The silencing of FBI-1 expression restores the ability of SAM68 to induce splicing of pro-apoptotic BCL-X S
41
. Another way to manipulate splicing is by targeting SAP155, a splicing factor which acts on MCL-1 and BCL-X. Inhibition of this protein by meaymycin B, and potent inhibitor of SAP155, has been used to switch splicing in favour of pro-apoptotic MCL-1s in cell culture 65 . Interestingly, the combination of meaymycin B with BH3-mimetic ABT-737 also induces apoptosis 65 . The activity of SAP155 has also been successfully downregulated using an anti-SAP155 antibody, which induced an increase in the pro-apoptotic BCL-X S isoform compared to BCL-X L , and this method can be used to prime the cell for response to apoptosis-inducing treatment 33 . Targeting splicing factors to favour the expression of pro-apoptosis isoforms is appealing but the non-specific nature of splicing factors will need to be addressed for this to be a superior target than BH3 mimetics. A more targeted approach to manipulating splicing is the use of specific antisense oligonucleotides. Antisense oligonucleotides designed to knock-down exon 2 in MCL-1 premRNA can shift splicing pattern from MCL-1L to MCL-1S 103 . This increases the expression of pro-apoptotic MCL-1S and reduces the level of anti-apoptotic MCL-1L, and was shown to induce apoptosis in basal cell carcinoma and gastric adenocarcinoma cell lines 103 . Manipulation of splicing remains an area of interest that requires further development to be a targeted as a treatment with clinical potential.
Summary
The BCL-2 family is involved in the regulation of apoptosis and therefore plays a vital role in protecting against cancer. Targeting the apoptotic pathway directly is a valid option for improving or developing new chemotherapies, but it is imperative that we understand the molecules, which we are attempting to modify, manipulate or mimic. As demonstrated in this review, there are gaps in knowledge regarding isoforms of anti-apoptotic BCL-2 family isoforms. Further studies focusing on understanding the variety of splice variants and isoforms and their biological role in apoptosis is required for targets of this pathway to reach their full potential. [144] [145] [146] [147] [148] [149] [150] was supported by the Cancer Institute NSW (14CDF117) and the Hunter
